Best Practice & Research Clinical Rheumatology
Volume 20, Issue 4 , Pages 791-807 , August 2006

Management of patients presenting with Sjogren's syndrome

  • P.J. Venables, MD, FRCP (Professor of Viral Immunorheumatology)

      Affiliations

    • Corresponding Author InformationAddress: Kennedy Institute Division, Imperial College, 1 Aspenlea Road, London W6 8LH, UK. Tel.: +44 208 3834444; Fax: +44 208 3834499.

References 

  1. Manoussakis MN, Moutsopoulos HM. Sjogren's syndrome: autoimmune epithelitis. Baillière's Best Practice & Research. Clinical Rheumatology. 2000;14:73–95
  2. Fox RI. Sjogren's syndrome. Lancet. 2005;366:321–331
  3. Vitali C, Bombardieri S, Moutsopoulos HM. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American–European consensus group. Annals of the Rheumatic Diseases. 2002;61:554–558
  4. Price EJ. Epithelial cell activation and Sjogren's syndrome. MD Thesis. Cardiff: University of Wales, 1997.
  5. Price EJ, Venables PJ. Dry eyes and mouth syndrome – a subgroup of patients presenting with sicca symptoms. Rheumatology (Oxford). 2002;41:416–422
  6. Fox RI. Sjogren's syndrome: evolving therapies. Expert Opinion on Investigational Drugs. 2003;12:247–254
  7. Mulherin D, Ainsworth JR, Hamburger J, et al. Survey of artificial tear and saliva usage among patients with Sjogren's syndrome. Annals of the Rheumatic Diseases. 2001;60:1077–1078
  8. Foster HE, Gilroy JJ, Kelly CA, et al. The treatment of sicca features in primary Sjogren's syndrome: a clinical review. British Journal of Rheumatology. 1994;33:278–282
  9. Dawson LJ, Smith PM, Moots RJ, Field EA. Sjogren's syndrome – time for a new approach. Rheumatology (Oxford). 2000;39:234–237
  10. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren's syndrome. Archives of Internal Medicine. 1999;159:174–181
  11. Vivino FB. The treatment of Sjogren's syndrome with pilocarpine tablets. Scandinavian Journal of Rheumatology. 2001;115(supplement):1–13
  12. Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis and Rheumatism. 2002;46:748–754
  13. Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Archives of Internal Medicine. 2002;162:1293–1300
  14. Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjogren's syndrome: a randomized, double-blind clinical study. American Journal of Ophthalmology. 2004;138:6–17
  15. Miyawaki S, Nishiyama S, Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren's syndrome. Internal Medicine. 1999;38:938–943
  16. Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjogren's syndrome with hydroxychloroquine; a retrospective, open-label study. Lupus. 1996;5:31–36
  17. Kruize AA, Hene RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjogren's syndrome; a two year, double blind cross over trial. Annals of the Rheumatic Diseases. 1993;52:60–64
  18. Cummins MJ, Papas A, Kammer GM, Fox PCMS. Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis and Rheumatism. 2003;49:585–593
  19. Bave U, Nordmark G, Lovgren T, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis and Rheumatism. 2005;52:1185–1195
  20. Yamada S, Mori K, Matsuo K, et al. Interferon alfa treatment for Sjogren's syndrome associated neuropathy. Journal of Neurology, Neurosurgery, and Psychiatry. 2005;76:576–578
  21. Unoki H, Moriyama A, Tabaru A, et al. Development of Sjogren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C. Journal of Gastroenterology. 1996;31:723–727
  22. Steinfeld SD, Demols P, Salmon I, et al. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis and Rheumatism. 2001;44:2371–2375
  23. Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjogren's syndrome: one-year followup. Arthritis and Rheumatism. 2002;46:3301–3303
  24. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis and Rheumatism. 2004;50:1270–1276
  25. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis and Rheumatism. 2004;50:2240–2245
  26. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis and Rheumatism. 2005;52:2740–2750
  27. Mandel L, Surattanont F. Bilateral parotid swelling: a review. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics. 2002;93:221–237
  28. Ramos-Casals M, Brito-Zeron P, Garcia-Carrasco M, Font J. Sarcoidosis or Sjogren syndrome? Clues to defining mimicry or coexistence in 59 cases. Medicine (Baltimore). 2004;83:85–95
  29. Mandel L, Wolinsky B, Chalom EC. Treatment of refractory sarcoidal parotid gland swelling in a previously reported unresponsive case. Journal of the American Dental Association. 2005;136:1282–1285
  30. Itescu S, Winchester R. Diffuse infiltrative lymphocytosis syndrome: a disorder occurring in human immunodeficiency virus-1 infection that may present as a sicca syndrome. Rheumatic Diseases Clinics of North America. 1992;18:683–697
  31. Kordossis T, Paikos S, Aroni K, et al. Prevalence of Sjogren's-like syndrome in a cohort of HIV-1-positive patients: descriptive pathology and immunopathology. British Journal of Rheumatology. 1998;37:691–695
  32. Terada K, Katamine S, Eguchi K, et al. Prevalence of serum and salivary antibodies to HTLV-1 in Sjogren's syndrome. Lancet. 1994;344:1116–1119
  33. Cimaz R, Casadei A, Rose C, et al. Primary Sjogren syndrome in the paediatric age: a multicentre survey. European Journal of Pediatrics. 2003;162:661–665
  34. Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjogren's syndrome: its effect on salivary and serum inflammatory markers. Annals of the Rheumatic Diseases. 1999;58:253–256
  35. Drage NA, Brown JE, Wilson RF, Shirlaw P. Sialographic changes in Sjogren's and SOX syndromes. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 1998;86:104–109
  36. Kassan SS, Thomas TL, Montsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Annals of Internal Medicine. 1978;89:888–892
  37. Thomas E, Hay EM, Hajeer A, Silman AJ. Sjogren's syndrome: a community-based study of prevalence and impact. British Journal of Rheumatology. 1998;37:1069–1076
  38. Tench C, Bentley D, Vleck V, et al. Aerobic fitness, fatigue, and physical disability in systemic lupus erythematosus. The Journal of Rheumatology. 2002;29:474–481
  39. Whiting P, Bagnall AM, Sowden AJ, et al. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA. 2001;286:1360–1368
  40. Gottenberg JE, Mignot S, Nicaise-Rolland P, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren's syndrome. Annals of the Rheumatic Diseases. 2005;64:114–117
  41. Moutsopoulos HM, Skopouli FN, Sarras AK, et al. Anti-Ro(SSA) positive rheumatoid arthritis (RA): a clinicoserological group of patients with high incidence of D-penicillamine side effects. Annals of the Rheumatic Diseases. 1985;44:215–219
  42. Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjogren's syndrome. Annals of the Rheumatic Diseases. 2000;59:709–712
  43. Szodoray P, Jonsson R, Brun JG, Zeher M. Polymyalgia rheumatica in primary Sjogren's syndrome. Rheumatology International. 2005;26:401–403
  44. Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. The Quarterly Journal of Medicine. 1990;77:1019–1038
  45. Vincent TL, Richardson MP, Mackworth-Young CG, et al. Sjogren's syndrome-associated myelopathy: response to immunosuppressive treatment. The American Journal of Medicine. 2003;114:145–148
  46. Van de Merwe J, Kamerling R, Arendsen E, et al. Sjogren's syndrome in patients with interstitial cystitis. The Journal of Rheumatology. 1993;20:962–966
  47. Pease CT, Shattles W, Charles PJ, et al. Clinical, serological and HLA phenotypes subsets in Sjogren's syndrome. Clinical and Experimental Rheumatology. 1989;17:185–190
  48. Goules A, Masouridi S, Tzioufas AG, et al. Clinically significant and biopsy-documented renal involvement in primary Sjogren syndrome. Medicine (Baltimore). 2000;79:241–249
  49. Bossini N, Savoldi S, Franceschini F, et al. Clinical and morphological features of kidney involvement in primary Sjogren's syndrome. Nephrology, Dialysis, Transplantation. 2001;16:2328–2336
  50. Soy M, Pamuk ON, Gerenli M, Celik Y. A primary Sjogren's syndrome patient with distal renal tubular acidosis, who presented with symptoms of hypokalemic periodic paralysis. Report of a case study and review of the literature. Rheumatology International. 2005;26:86–89
  51. Tseng CE, Buyon JP. Neonatal lupus syndromes. Rheumatic Diseases Clinics of North America. 1997;23:31–54

PII: S1521-6942(06)00051-9

doi: 10.1016/j.berh.2006.05.003

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 4 , Pages 791-807 , August 2006

Article Tools